Thanks RTB. I suspected as much. Each have our own numbers, and those numbers explain the difference. And each person should run their own numbers and risk. Also, yes, your numbers are closer to current market value. I can understand why the FDA was asking for 700mg safety data given mono 350mg vs 700mg, which delayed the BLA, and don't see another issue of that nature. The market just sees a trend and predict that trend will continue. With the last several BLA delays, the market is expecting that to be the new trend, delay, delay, delay, delay. I think the market value is wrong. We will see.

I also don't worry about bk as much, having following many otc companies, almost all have horrible finances but few end up bk, because if it comes to bk and a r/s, shareholder pick r/s every time. Also the noteholder's convertible is restricted, unlike toxic financing, which makes it harder for them to press the sp to zero. Just as long as combo approval is an option, there will be interested parties buying shares. If we were at phase 1, with years to go, I would be much more concerned. With with phase 3 already approved, greed works on both sides, i.e. people interested in taking on the risk with the that possible heavy reward very close... just my opinion.